Apolipoprotein E (apoE) is a 34-kDa protein found in plasma associated with several classes of lipoproteins with a primary function in cholesterol and lipid transport ([@B1]). It is expressed in most cell types, including hepatocytes, smooth muscle, macrophages, adipocytes, and the central nervous system ([@B1]). In addition to facilitating lipid transport between various tissues and organs, apoE also has lipid transport--independent functions, such as the modulation of cell signaling, oxidation, and enzyme activation ([@B2]). Both lipid transport--dependent and --independent functions of apoE can modulate the progression and severity of a wide spectrum of metabolic diseases. The human *APOE* gene exists with three major polymorphic alleles. The most common allele, with a frequency of ∼75%, is ε3, which imparts metabolic benefits due to the anti-inflammatory and antioxidative properties of apoE3. The ε4 allele, with a frequency of ∼15%, encodes apoE4, which is proinflammatory and thus increases the risk for both cardiovascular disease and neurodegenerative disorders such as Alzheimer disease ([@B1],[@B2]).

The relationship between the ε2 allele with metabolic disease risk is less clear. Typically, ε2 carriers have lower plasma cholesterol levels ([@B3]) but tend to have higher plasma triglyceride levels and are prone to developing type III dyslipoproteinemia ([@B3],[@B4]), putting them at greater risk for metabolic-associated diseases. Although several independent studies have failed to identify an association between ε2 mutation and risk of type 2 diabetes ([@B5]--[@B8]), genetic studies in two other populations have revealed the association of the ε2 allele with higher BMI (odds ratio 3.55) and waist circumference (odds ratio 3.3) ([@B4],[@B9]). A large-scale meta-analysis combining data from 30 independent studies showed that ε2 carriers have a moderately increased risk of developing type 2 diabetes ([@B10]). Diabetic ε2 carriers also have a twofold increased risk and severity of coronary artery disease compared with ε3 patients with diabetes ([@B11],[@B12]). In nondiabetic patients, the ε2 allele is an independent risk factor for end-stage renal disease, peripheral vascular diseases such as cerebrovascular disease and ischemia of lower extremity arteries, and carotid atherosclerosis ([@B13]--[@B16]). The mechanism(s) underlying the contribution of apoE2 toward obesity, diabetes, and peripheral vascular disease has not been elucidated.

A well-established role of apoE is its ability to bind LDL receptor family proteins to mediate clearance of triglyceride-rich lipoproteins from circulation ([@B1]). ApoE2 is defective in binding to the LDL receptor ([@B1]). Although the majority of ε2 homozygotes have normal or even lower plasma cholesterol levels ([@B1]), almost all heterozygous and homozygous ε2 carriers have elevated triglyceride levels due to impaired hepatic clearance of triglyceride-rich lipoproteins, including the chylomicron remnants derived postprandially after a fatty meal ([@B1],[@B17]). With increasing evidence suggesting that the postprandial increase of plasma triglyceride levels promotes systemic inflammation ([@B18]--[@B23]), which increases the risk of metabolic diseases ([@B22],[@B23]), it is reasonable to postulate that the elevated metabolic disease risk associated with the ε2 allele may be due to sustained postprandial inflammation as a consequence of delayed postprandial triglyceride-rich lipoprotein clearance. To test this hypothesis, this study compared fatty meal--induced postprandial inflammation between mice in which the endogenous mouse *apoE* gene has been replaced by either the human *APOE2* or *APOE3* gene. The consequence of chronic high-fat feeding on tissue inflammation and obesity/diabetes development between *APOE2* and *APOE3* gene replacement mice was also explored.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Animals and diets. {#s2}
------------------

Gene replacement mice, in which the endogenous mouse *apoE* gene has been replaced at the same locus with the human *APOE2* or *APOE3* gene ([@B24],[@B25]), hereafter designated as *APOE2* and *APOE3* mice, were purchased from Taconic (Hudson, NY), where they were back-crossed to C57BL/6 background through nine and eight generations, respectively. The human *APOE* genotypes in these animals were confirmed by restriction isotyping after gene amplification as previously described ([@B26]). The mice were fed either chow (Teklad, Madison, WI) or a Western-type, high-fat, high-cholesterol diet containing 21.2% fat and 0.2% cholesterol (TD88137; Teklad). Animals were maintained under controlled environmental conditions with free access to food and water. All animal protocols were approved by the University of Cincinnati Institutional Animal Use and Care Committee.

Weight and adiposity measurements. {#s3}
----------------------------------

Age-matched *APOE2* and *APOE3* mice were housed according to their genotype with one to three mice per cage. Food consumption was monitored daily over a 1-week period. No obvious difference in the average amounts of food consumed per animal was observed regardless of housing conditions. Body weight and adiposity measurements were performed every 2 weeks. Weights were obtained using a Denver 300 K scale. Adiposity measurements were obtained using an EchoMRI Whole-Body Composition Analyzer (Echo Medical Systems, Houston, TX), as described previously ([@B27]).

Blood chemistry. {#s4}
----------------

Blood was collected from mice after an overnight fast. Blood glucose was determined with an Accu-Chek Active Glucometer (Roche Applied Science, Indianapolis, IN). Plasma insulin levels were measured with the Ultra Sensitive Rat Insulin ELISA kit (Crystal Chem, Chicago, IL). Plasma adiponectin levels were measured by mouse Adiponectin/Acrp30 DuoSet ELISA (R&D Systems, Minneapolis, MN). Plasma levels of leptin and other cytokines were determined using MILLIPLEX MAP Mouse Adipokine Panel (Millipore, St. Charles, MO). Plasma cholesterol and triglycerides were determined using Infinity cholesterol and triglyceride kits (Thermo Fisher Scientific, Middletown, NJ). Samples from each mouse were analyzed individually except for lipoprotein separation, in which two separately pooled samples, each with 0.25 mL plasma from three animals in each group, were subjected to fast-performance liquid chromatography (FPLC) gel filtration on two Superose 6 columns connected in series. Individual fractions in the FPLC were analyzed based on cholesterol content and by Western blot analysis with goat anti-human apoB (Millipore) and rabbit anti-human apoE (Dako) antibodies at 1:5,000 dilutions, as described previously ([@B28]).

Postprandial lipid clearance. {#s5}
-----------------------------

Mice were fasted overnight and then fed a bolus lipid-rich meal (15 µL olive oil and 0.2 µCi \[^14^C\]triolein per gram body weight) by stomach gavage. Blood (50 µL) was obtained from the tail vein before and 15, 30, 60, 120, and 180 min afterward. Plasma was obtained after centrifugation and used to measure triglyceride levels and determine radioactivity by liquid scintillation counting.

Glucose tolerance and insulin sensitivity tests. {#s6}
------------------------------------------------

A glucose solution was administered orally by stomach gavage to chow-fed *APOE2* and *APOE3* mice (2 g/kg body weight) after an overnight fast. Insulin sensitivity was monitored by intraperitoneal injection of 0.75 units pig insulin per gram body weight after a 10-h fast. Blood was obtained from the tail vein before and every 15 min after glucose or insulin administration to measure glucose levels.

Adipose tissue histology. {#s7}
-------------------------

Subcutaneous (inguinal) and visceral (gonadal) adipose tissues were fixed in isotonic neutral 4% paraformaldehyde solutions prior to embedding in paraffin. Three 5-µm sections from different levels of each depot obtained from each mouse (four *APOE2* and six *APOE3* mice) were analyzed for adipocyte size and crown-like structures after staining with hematoxylin and eosin. Adipocyte sizes were determined as adipocyte area of 480 random adipocytes. Crown-like structures, indicative of inflammatory macrophages surrounding dead adipocytes ([@B29]), were identified based on aggregates of nucleated cells surrounding individual adipocytes. Crown-like structure density was obtained by counting the total number in each section compared with the total number of adipocytes.

RNA quantification. {#s8}
-------------------

Total RNA was isolated with TRIzol reagent (Invitrogen) and treated with Turbo DNase (Applied Biosystems/Ambion, Austin, TX). cDNA was generated using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Quantitative real-time PCR was performed on a StepOnePlus Fast Thermocycler using Fast SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA) with primer sequences as shown in [Table 1](#T1){ref-type="table"}.

###### 

Primer sequences used for RT-PCR amplification of RNA

![](382tbl1)

Flow cytometry. {#s9}
---------------

Flow cytometry analysis was performed on a Guava EasyCyte 8HT System and analyzed using Guava InCyte (Millipore, Hayward, CA). In brief, mice fasted overnight were given an oral gavage of 200 μL olive oil. Blood was collected from the submandibular vein in heparinized tubes before and 2 h after the gavage. Erythrocytes were lysed with RBC lysis buffer (eBioscience, San Diego, CA) for 10 min at room temperature twice and then washed once in flow cytometry staining buffer (FCSB; Ca^2+^/Mg^2+^-free Hanks' balanced salt solution with 0.3% NaN~3~ and 1% BSA \[fraction V; Sigma\]). FCSB was used for all washes and antibody incubations unless otherwise indicated. All remaining incubations were carried out at 4°C. Nonspecific binding was blocked using CD16/32 antibody (eBioscience, San Diego, CA). Cells were washed and incubated for 45 min with various extracellular-labeling antibodies at 1:25 dilution and then fixed in 2% paraformaldehyde solution overnight. Cells were permeabilized with BD Cytofix/Cytoperm Plus Kit (BD Biosciences, Franklin Lakes, NJ), incubated with 1:25 dilutions of antibodies specific for intracellular markers, and subjected to flow cytometry analysis. Conjugated antibodies to nitric oxide synthase (NOS2), Lys6G, and CD11b were purchased from BD Biosciences. For neutral lipid staining, leukocytes were incubated with HCS LipidTOX (Invitrogen) at 1:100 for 1 h prior to flow cytometry analysis. The magnitude of lipid accumulation was determined based on green fluorescent intensity measured at 488-nm excitation and 518-nm emission. Adipose tissue macrophage content was assessed based on positive staining of stromal-vascular cells with F4/80 antibodies (eBioscience) after enzymatic tissue disaggregation with type I collagenase (Worthington, Lakewood, NJ).

Statistics. {#s10}
-----------

Statistical analyses were performed using Microsoft Excel spreadsheet or SigmaPlot version 11.0 software. Data are expressed as means ± SDs, except where noted in the figure legend. Differences were considered significant at *P* \< 0.05 based on ANOVA analyses with Bonferroni post hoc test or Student *t* test.

RESULTS {#s11}
=======

Prolonged postprandial hypertriglyceridemia in *APOE2* mice. {#s12}
------------------------------------------------------------

Male *APOE2* and *APOE3* mice were placed on either a basal rodent chow and/or fed a Western-type, high-fat, high-cholesterol diet beginning at 6 weeks of age. Fasting plasma lipid levels were determined after 4 weeks. Consistent with results reported previously ([@B27],[@B28]), *APOE2* mice have significantly higher plasma triglyceride and cholesterol levels compared with the *APOE3* mice under both dietary conditions ([Fig. 1*A*](#F1){ref-type="fig"} and [*B*](#F1){ref-type="fig"}). Interestingly, plasma triglyceride levels in *APOE2* mice fed the basal diet were higher and their plasma cholesterol levels were similar to *APOE3* mice fed the Western-type diet. Hyperlipidemia was further exaggerated in *APOE2* mice after feeding the Western-type diet ([Fig. 1*A* and *B*](#F1){ref-type="fig"}). When the mice maintained on basal diet were challenged with a bolus lipid-rich meal of olive oil containing \[^14^C\]triolein, delayed plasma clearance of the radiolabeled lipids, indicative of defective triglyceride-rich lipoprotein clearance, was observed in *APOE2* mice ([Fig. 1*C*](#F1){ref-type="fig"}). The impaired clearance of postprandial, triglyceride-rich lipoproteins resulted in robust postprandial hyperlipidemia in the *APOE2* mice ([Fig. 1*D*](#F1){ref-type="fig"}). Analysis of lipoproteins in chow- and Western diet--fed mice under both fasting and postprandial conditions by FPLC revealed the accumulation of VLDL and LDL in the *APOE2* mice ([Fig. 1*E* and *F*](#F1){ref-type="fig"}). Western blot analysis confirmed the accumulation of apoB100- and apoB48-containing lipoproteins with excess apoE in *APOE2* mice compared with *APOE3* mice ([Fig. 1*E* and *F*](#F1){ref-type="fig"}). These results illustrated that *APOE2* mice recapitulated the abnormal lipoprotein metabolism in ε2 human subjects, and thus can be used to assess the influence of apoE2 on metabolic diseases.

![Plasma lipid levels in *APOE2* and *APOE3* mice. *A*: Fasting triglyceride levels. *B*: Fasting cholesterol levels in *APOE2* and *APOE3* mice fed chow diet (filled bars) and after feeding the Western-type diet for 4 weeks (open bars). Bars with different letters were different at *P* \< 0.05 (*n* = 6). *C*: Postprandial clearance of \[^14^C\]lipids from plasma after feeding *APOE2* (open symbols) and *APOE3* (filled symbols) mice an olive oil meal containing \[^14^C\]triolein. *D*: Postprandial plasma triglyceride levels in chow-fed *APOE2* (open symbols) and *APOE3* (filled symbols) 2 h after oral feeding a lipid-rich meal. The data in *C* and *D* represent mean ± SD from four mice in each group, with \* and \# indicating significant differences from the *APOE3* mice at *P* \< 0.05 and *P* \< 0.01, respectively. *E* and *F*: FPLC profiles from *APOE2* (open symbols) and *APOE3* mice (filled symbols) under both fasting (circle symbols) and postprandial (triangle symbols) conditions. The insets show Western blots of apoB100, apoB48, and apoE bands in VLDL (fractions 3--6) and IDL/LDL (fractions 18--21) of fasted (F) and postprandial (P) *APOE2* (2F and 2P) and *APOE3* (3F and 3P) mice. Note that the apoB proteins in *APOE3* mice were barely detectable by Western blots.](382fig1){#F1}

Elevated postprandial inflammation in *APOE2* mice. {#s13}
---------------------------------------------------

Triglyceride-rich lipoproteins and postprandial lipidemia are major risk factors for metabolic and vascular diseases because of their direct influence on leukocyte activation, with increased neutrophil cell count and activation to exacerbate inflammation ([@B19],[@B20],[@B30],[@B31]). Therefore, we also examined the role of the apoE2-associated delay in postprandial triglyceride-rich lipoprotein clearance on inflammation. Blood from chow-fed *APOE2* and *APOE3* mice was collected after an overnight fast and 2 h after a bolus olive oil meal for flow cytometry analysis. Whereas no differences in the number of granulocytes, monocytes, and lymphocytes were observed between *APOE2* and *APOE3* mice during the fasting state, the *APOE2* mice had a significantly higher number of granulocytes compared with *APOE3* mice during the postprandial period ([Fig. 2*A*--*C*](#F2){ref-type="fig"}). Both *APOE2* and *APOE3* mice also exhibited reduced levels of monocytes in circulation postprandially, but no statistically significant differences were observed between *APOE2* and *APOE3* mice ([Fig. 2*C*](#F2){ref-type="fig"}). Interestingly, a significant increase in neutral lipid accumulation in neutrophils was observed in *APOE2* mice compared with *APOE3* mice 2 h after a bolus lipid-rich meal ([Fig. 2*D*--*F*](#F2){ref-type="fig"}). These observations indicate that delayed clearance of apoE2-containing, triglyceride-rich lipoproteins leads to their elevated transport to granulocytes, a process that may promote systemic inflammation ([@B19],[@B20]). Indeed, whereas fasting *APOE2* mice showed no differences in either CD11b^+^Ly6G^+^ granulocytes or granulocyte expression of inducible NOS2 compared with *APOE3* mice, significantly higher numbers of both NOS2^+^ and CD11b^+^Ly6G^+^ granulocytes were observed in *APOE2* mice during the postprandial period compared with those observed in *APOE3* mice ([Fig. 2*G* and *H*](#F2){ref-type="fig"}).

![Flow cytometry analysis of blood leukocytes in *APOE2* and *APOE3* mice. *A* and *B*: Representative plots of blood cells showing forward and side scattering of lymphocytes (L), monocytes (M), and granulocytes (G) from *APOE2* and *APOE3* mice, respectively, 2 h after feeding a lipid-rich meal. *C*: Bar graph showing the average number of each cell type ± SD in four *APOE2* (open bars) and six *APOE3* (filled bars) mice after overnight fast and 2 h after feeding a lipid-rich meal. \**P* \< 0.05, difference from fasted mice of the same genotype; \#*P* \< 0.05, difference from *APOE3* mice under same treatment conditions (*n* = 6 in each group). *D* and *E*: Representative histogram of granulocytes after staining with the fluorescent neutral lipid stain LipidTox. *F*: Bar graph showing mean neutral lipid staining intensity ± SD from four *APOE2* (open bars) and eight *APOE3* (filled bars) mice before (fasted) and 2 h after lipid meal feeding (postprandial). \**P* \< 0.05, difference from the *APOE3* mice. *G*: Inducible NOS (iNOS)--positive neutrophils. *H*: CD11b and Ly6G double-positive cells as the mean percentage of total leukocytes ± SD in the blood of four *APOE2* (open bars) and six *APOE3* (filled bars) mice before (fasted) or 2 h after feeding a lipid-rich meal (fed). \**P* \< 0.05, difference from *APOE3* mice under same feeding conditions (*n* = 6).](382fig2){#F2}

ApoE2 promotes diet-induced obesity and insulin resistance. {#s14}
-----------------------------------------------------------

The delay in postprandial triglyceride-rich lipoprotein clearance may also increase the partitioning of dietary fat to adipose tissues for storage. To test this possibility, we compared the body weights of *APOE2* and *APOE3* mice maintained on basal chow diet and then monitored their body weights in response to Western diet feeding. Results showed that 10-week-old male *APOE2* mice were slightly heavier than *APOE3* mice on chow diet ([Fig. 3*A*](#F3){ref-type="fig"}). After Western diet feeding for 4 weeks, the *APOE2* mice gained significantly more weight compared with the *APOE3* mice ([Fig. 3*A*](#F3){ref-type="fig"}). Analysis of body composition by nuclear magnetic resonance revealed that the differences in body weight gain between *APOE2* and *APOE3* mice were due to significantly higher body fat content in *APOE2* mice ([Fig. 3*B*](#F3){ref-type="fig"}).

![Body weights and adiposity of *APOE2* and *APOE3* mice. Bar graphs showing mean body weights ± SD (*A*) and percent body fat ± SD (*B*) in 10-week-old male *APOE2* and *APOE3* mice fed either chow diet (filled bars) or 4 weeks after feeding the Western-type diet (open bars). \**P* \< 0.05, difference from chow-fed mice (*n* = 6).](382fig3){#F3}

Fasting glucose levels were similar between *APOE2* and *APOE3* mice under basal dietary conditions. Both groups of mice showed a slight but statistically insignificant increase in fasting glucose levels, but their fasting insulin levels were significantly elevated after 4 weeks on Western-type diet ([Fig. 4*A*](#F4){ref-type="fig"} and [*B*](#F4){ref-type="fig"}). Interestingly, fasting insulin levels were higher in *APOE2* mice compared with *APOE3* mice under both dietary conditions. In fact, fasting insulin levels in chow-fed *APOE2* mice were similar to those observed in *APOE3* mice fed the Western-type diet for 4 weeks ([Fig. 4*B*](#F4){ref-type="fig"}), and the Western diet further elevated fasting insulin levels in *APOE2* mice to levels approximately three times higher than those observed in Western diet--fed *APOE3* mice ([Fig. 4*B*](#F4){ref-type="fig"}). Calculations of homeostasis model assessment of insulin resistance index suggested that *APOE2* mice are prediabetic with hyperinsulinemia even under basal dietary conditions ([Fig. 4*C*](#F4){ref-type="fig"}). This hypothesis was confirmed by data showing a small but statistically significant increase of glucose intolerance in chow-fed *APOE2* mice after an oral glucose load ([Fig. 4*D*](#F4){ref-type="fig"}), despite their elevated plasma insulin levels compared with *APOE3* mice ([Fig. 4*B*](#F4){ref-type="fig"}). The insulin resistance phenotype of *APOE2* mice was further confirmed by insulin tolerance tests, showing their delayed glucose disposal after insulin injection compared with that observed in *APOE3* mice ([Fig. 4*E*](#F4){ref-type="fig"}).

![Blood glucose and insulin levels. *A*: Mean fasting blood glucose ± SD. *B*: Fasting plasma insulin levels ± SD. *C*: Calculations of homeostasis model assessment of insulin resistance (HOMA) index in chow- (filled bars) and Western diet--fed (open bars) *APOE2* and *APOE3* mice. Bars with different letters denote significant differences at *P* \< 0.05, whereas bars with similar letters were not statistically different (*n* = 6). Glucose tolerance tests with inset showing area under the curve (AUC) analysis (*D*) and insulin sensitivity tests (*E*) in *APOE2* (open symbols) and *APOE3* (filled symbols) mice. The data represent the mean from six mice in each group. \**P* \< 0.05, difference from the *APOE3* mice. A.U., arbitrary units.](382fig4){#F4}

ApoE2 promotes adipocyte dysfunction and inflammation. {#s15}
------------------------------------------------------

The robust diet-induced obesity and hyperinsulinemia along with elevated postprandial systemic inflammation observed in the *APOE2* mice suggests their potential increased susceptibility to diet-induced adipocyte dysfunction and inflammation compared with *APOE3* mice. Therefore, subcutaneous (inguinal) and visceral (gonadal) fat depots were harvested from *APOE2* and *APOE3* mice fed either basal or Western diet for 4 weeks for comparison. Histological examination of the adipose tissues revealed larger adipocytes in subcutaneous depots of *APOE2* mice compared with *APOE3* mice under chow-fed conditions ([Fig. 5*A*](#F5){ref-type="fig"} and [*B*](#F5){ref-type="fig"}). Significant enlargement of the adipocytes in both depots of *APOE2* and *APOE3* mice was observed after Western diet feeding, but the differences between *APOE2* and *APOE3* mice were no longer noticeable ([Fig. 5*A* and *B*](#F5){ref-type="fig"}). The most striking difference between *APOE2* and *APOE3* mice was the prevalence of crown-like structures, indicative of dead adipocytes surrounded by macrophages ([@B29]), in the adipose tissues of *APOE2* mice ([Fig. 5*C*](#F5){ref-type="fig"}). Although *APOE3* mice displayed a minimal, if any, number of crown-like structures in both subcutaneous and visceral adipose tissues under chow-fed conditions, and their presence was detectable only sporadically after 4 weeks of feeding with the Western-type diet, the crown-like structures were detectable consistently in both subcutaneous and visceral adipose depots of *APOE2* mice even when maintained under chow-fed conditions ([Fig. 5*C*](#F5){ref-type="fig"}). The number of crown-like structures was further increased in both adipose depots of *APOE2* mice after Western diet feeding ([Fig. 5*C*](#F5){ref-type="fig"}). The presence of crown-like structures, and their subsequent increase with Western diet feeding in adipose tissues of *APOE2* mice, is consistent with the interpretation that apoE2 promotes adipocyte dysfunction and increases susceptibility to diet-induced inflammation.

![Adipose tissue histology. *A*: Histological analysis of subcutaneous (inguinal) and visceral (gonadal) adipose tissues of *APOE2* and *APOE3* mice fed either chow diet or after feeding the Western diet for 4 weeks. Arrows point to representative crown-like structures in each image. Bars, 50 µm. *B*: Distribution of adipocyte cell sizes in subcutaneous (inguinal) and visceral (gonadal) adipose tissues of chow- and Western diet--fed *APOE2* (dotted lines) and *APOE3* (solid lines) mice. The data were obtained by measuring areas of 480 random adipocytes from three random fields from each mouse (*n* = 4 *APOE2* and 6 *APOE3* mice). *C*: Number of crown-like structures in subcutaneous and visceral adipose tissues of chow- and Western diet--fed *APOE2* (open bars) and *APOE3* (filled bars) mice. The data were obtained by counting the total number in each section compared with the total number of adipocytes and reported as mean ± SE. \**P* \< 0.05, significant difference from the *APOE3* mice; \#*P* \< 0.01, significant difference from the *APOE3* mice.](382fig5){#F5}

The analysis of adipokine expression revealed significantly elevated leptin expression in both subcutaneous and visceral adipose tissues after Western diet feeding ([Fig. 6*A*](#F6){ref-type="fig"}). Consistent with results showing exaggerated diet-induced adiposity in *APOE2* mice, diet-induced leptin expression was also higher in the *APOE2* mice compared with *APOE3* mice ([Fig. 6*A*](#F6){ref-type="fig"}). Interestingly, adiponectin expression levels were similar between chow- and Western diet--fed *APOE2* mice, whereas adiponectin expression levels in the subcutaneous tissue of *APOE3* mice were higher after Western diet feeding ([Fig. 6*B*](#F6){ref-type="fig"}). As a result, adiponectin-to-leptin ratios in subcutaneous and visceral fat depots were lower in *APOE2* mice, and the differences were further exaggerated upon Western diet feeding. These data provided additional support for the elevated basal inflammation (dysfunction) of both subcutaneous and visceral fat depots of *APOE2* mice, and the condition was further exaggerated when fed the Western-type diet.

![Gene expression in adipose tissues. Total mRNA was isolated from subcutaneous and visceral adipose tissues of chow- (filled bars) and Western diet--fed (open bars) *APOE2* and *APOE3* mice and used for quantification by qPCR. Gene expression levels were normalized to levels of cyclophilin gene expression. *A*: Leptin expression levels. *B*: Adiponectin expression levels. *C*: MCP-1 expression levels.*D*: MIP-1α expression levels. *E*: Macrophage marker gene F4/80 expression levels. *F*: TNF-α expression levels. *G*: Inducible NOS2 expression levels. *H*: MRC2 expression levels. The data were reported as mean *±* SD from six mice in each group. \**P* \< 0.05, difference from mice with the same genotype fed chow diet; \#*P* \< 0.05, difference from mice with different genotype fed the same diet.](382fig6){#F6}

Elevated adipose tissue macrophage content and inflammation in *APOE2* mice. {#s16}
----------------------------------------------------------------------------

To further test the hypothesis that adipose tissues in *APOE2* mice are dysfunctional (more inflamed), macrophage recruitment and retention marker gene expression in both subcutaneous (inguinal) and visceral (gonadal) adipose depots were compared between basal and Western diet--fed *APOE2* and *APOE3* mice. In subcutaneous adipose tissues, no significant differences in expression of monocyte chemoattractant protein-1 (MCP-1) and MIP-1α were observed between *APOE2* and *APOE3* mice under basal dietary conditions, with elevated MIP-1α expression observed in *APOE2* mice after feeding the Western-type diet for 4 weeks ([Fig. 6*C* and *D*](#F6){ref-type="fig"}). Interestingly, the number of macrophages, as measured by F4/80 mRNA, was significantly higher (by approximately twofold) in subcutaneous adipose of *APOE2* mice compared with *APOE3* mice ([Fig. 6*E*](#F6){ref-type="fig"}), indicating elevated basal inflammation even in subcutaneous adipose of *APOE2* mice. The influence of *APOE2* on diet-induced adipose tissue inflammation was readily observed in visceral adipose tissues, with MCP-1, MIP-1α, and F4/80 gene expression elevated three- to fourfold in *APOE2* mice, whereas expression of these genes was not significantly different in *APOE3* mice after 4 weeks on Western diet ([Fig. 6*C*--*E*](#F6){ref-type="fig"}). The elevated expression of F4/80 genes in adipose tissues of *APOE2* mice compared with *APOE3* mice was consistent with a similar increase of F4/80^+^ cells in the stromal-vascular cell fractions of *APOE2* adipose tissues observed by flow cytometry (*APOE2* mice, 47.54% macrophages; *APOE3* mice, 33.68% macrophages; *P* \< 0.05).

The expression of proinflammatory M1 macrophage marker genes, such as tumor necrosis factor-α (TNF-α) and NOS2 ([@B32]), was also significantly elevated in subcutaneous adipose tissues of *APOE2* mice compared with *APOE3* mice under both basal and Western diet conditions. In fact, the expression of both TNF-α and NOS2 in chow-fed *APOE2* mice was similar to that observed in Western diet--fed *APOE3* mice ([Fig. 6*F* and *G*](#F6){ref-type="fig"}). Western diet feeding further exaggerated the elevated expression of NOS2 in subcutaneous adipose tissues of *APOE2* mice ([Fig. 6*G*](#F6){ref-type="fig"}). Likewise, in the more inflammatory visceral adipose tissues, TNF-α expression was similar between basal diet--fed *APOE2* mice and *APOE3* mice fed either diet. The expression of TNF-α in visceral fat depots of *APOE2* mice, but not *APOE3* mice, was additionally increased after feeding the Western diet for 4 weeks ([Fig. 6*F*](#F6){ref-type="fig"}). The expression of NOS2 in visceral depots was similar and diet responsive in both *APOE2* and *APOE3* mice ([Fig. 6*G*](#F6){ref-type="fig"}). Surprisingly, the expression levels of alternative macrophage activation genes, such as the type 2 mannose receptor (MRC2) ([@B31]), were also significantly higher in subcutaneous adipose tissues of basal diet--fed *APOE2* mice, to a level similar to that observed in *APOE3* mice after Western diet feeding. Western diet further exaggerated alternative macrophage activation in subcutaneous adipose tissues of *APOE2* mice ([Fig. 6*H*](#F6){ref-type="fig"}). In the typically more inflamed visceral adipose depots, no significant differences in MRC2 expression were observed between basal chow--fed *APOE2* and *APOE3* mice, and both strains responded to Western diet feeding with similar induction of MRC2 ([Fig. 6*H*](#F6){ref-type="fig"}). Similar results were obtained using arginase-1 mRNA as a marker of M2 macrophages (data not shown). Taken together, these results indicate that macrophages in subcutaneous adipose tissues of *APOE2* mice are more activated compared with *APOE3* mice through both classical and alternative activation pathways, whereas both strains are sensitive to diet-induced activation of visceral adipose tissue macrophages.

Elevated plasma cytokine levels in *APOE2* mice. {#s17}
------------------------------------------------

In addition to differences in gene expression between adipose tissues isolated from *APOE2* and *APOE3* mice, we also measured plasma levels of adipokines and inflammatory cytokines in these animals. Consistent with the gene expression data, no difference in plasma adiponectin levels was observed between *APOE2* and *APOE3* mice ([Fig. 7*A*](#F7){ref-type="fig"}). In contrast, significantly higher levels of leptin, interleukin-6, and plasminogen activator inhibitor-1 were observed in the plasma of *APOE2* mice ([Fig. 7*B*--*D*](#F7){ref-type="fig"}).

![Plasma cytokine levels. Plasma was obtained from *APOE2* (open bars) and *APOE3* (filled bars) to determine the levels of adiponectin (*A*), leptin (*B*), interleukin-6 (*C*), and plasminogen activator inhibitor-1 (PAI-1) (*D*). The data represent mean ± SD from six mice in each group. \**P* \< 0.05, significant difference from *APOE3* mice.](382fig7){#F7}

DISCUSSION {#s18}
==========

Human population studies have suggested that the apoE2-encoding ε2 allele may be a genetic modifier for increased risk of developing obesity and type 2 diabetes ([@B4],[@B9],[@B10]). The current study used human *APOE2* and *APOE3* gene replacement mice and showed that the underlying mechanism is the impaired clearance of apoE2-containing triglyceride-rich lipoproteins from circulation, leading to increased postprandial lipid uptake by leukocytes to promote inflammation, and chronic lipid deposition in adipose tissues to increase adiposity and susceptibility to diet-induced obesity. The combination of elevated adiposity and inflammation accelerates adipose tissue dysfunction, with increased macrophage infiltration and inflammation observed in adipose tissues of *APOE2* mice after a short 4-week dietary regimen. The consequence of these metabolic changes is the accelerated hyperinsulinemia observed in Western diet--fed *APOE2* mice compared with *APOE3* mice.

The mechanism by which apoE2 promotes postprandial lipid uptake by leukocytes and chronic lipid deposition in adipose tissues has not been established. Typically, lipids from triglyceride-rich lipoproteins are taken up by leukocytes and adipocytes through two distinct mechanisms, one involving lipoprotein lipase--mediated hydrolysis of the triglycerides followed by the uptake of the liberated fatty acids ([@B33],[@B34]) and another via whole lipoprotein particle endocytosis after binding to LDL receptor--related protein-1 (LRP1), VLDL receptor, and/or heparin sulfate proteoglycans (HSPGs) ([@B27],[@B35],[@B36]). Previous studies have shown that apoE2-containing lipoproteins are poor substrates for lipoprotein lipase in comparison with apoE3 lipoproteins ([@B37]). Moreover, lipoprotein lipase expression was reported to be similar between *APOE2* and *APOE3* mice, but the *APOE2* adipocytes are defective in the uptake of lipase-derived fatty acids ([@B38]). Importantly, despite the defective binding of apoE2 lipoproteins to the LDL receptor, apoE2 lipoproteins bind with similar affinity as apoE3 lipoproteins to LRP1, VLDL receptor, and HSPG ([@B39]--[@B43]). Previous studies have shown the importance of LRP1, VLDL receptor, and HSPG in mediating lipid deposition in adipocytes ([@B27],[@B35],[@B36]). The receptor-associated protein, which binds to both LRP1 and VLDL receptor in inhibiting their interaction with apoE-containing lipoproteins, has also been reported to suppress triglyceride-rich lipoprotein-induced leukocyte activation ([@B19]). Thus, it appears more likely that the elevated postprandial leukocyte lipid uptake and inflammation as well as the chronic dietary lipid deposition in *APOE2* mice are mediated through apoE2-containing triglyceride-rich lipoprotein endocytosis via one of the cell surface receptors. Nevertheless, additional studies are necessary to test this hypothesis.

It is interesting to note that *APOE2* adipocytes were previously reported to have an increased rate of stored triglyceride hydrolysis as well as impaired de novo lipogenesis compared with *APOE3* adipocytes ([@B38]). Despite these abnormalities, we observed elevated obesity with increased adipocyte cell size in *APOE2* mice compared with *APOE3* mice upon chronic feeding of the Western-type diet. These observations illustrated that the impaired hepatic clearance of apoE2-containing triglyceride-rich lipoproteins leads to redistribution of dietary fat to adipocytes in *APOE2* mice to promote obesity. Moreover, the elevated hydrolysis and turnover of stored triglycerides is also expected to promote adipocyte lipotoxicity to exacerbate inflammation ([@B44]). The observation of an increased number of crown-like structures, representing macrophage aggregates surrounding dead adipocytes ([@B29]), in *APOE2* adipose tissues compared with *APOE3* adipose tissues is consistent with this interpretation.

In summary, our data showed increased sensitivity to postprandial inflammation and diet-induced obesity in mice expressing human apoE2 compared with apoE3. It is important to note that, in contrast to human ε2 carriers, the *APOE2* mice displayed hyperlipidemia even under low-fat, chow-fed conditions. There are also significant differences in triglyceride-rich lipoprotein metabolism between mice and humans. Determining whether human ε2 carriers are also more sensitive to postprandial inflammation and diet-induced obesity compared with ε3 subjects will require additional studies.
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